For first-in-class oncology drugs 2010-2020 (n=50)
'Remarkably, the number of drugs that originate from academic research alone was on par with that originated by large pharma (each 14% of our sample).'
https://www.sciencedirect.com/science/article/pii/S1359644622004494?via%3Dihub
Thiago Carvalho /
npub1xa…czham
2024-08-18 18:17:43
Author Public Key
npub1xakev87fgm9edqu6f5jhszwunekjxl3dpnq4sxvm3nzu2ace8xnqyczhamPublished at
2024-08-18 18:17:43Event JSON
{
"id": "084779ee5490c4bcbc33f7cf696468de44e4bb364255d347c14193c865cdc87e",
"pubkey": "376d961fc946cb96839a4d257809dc9e6d237e2d0cc158199b8cc5c5771939a6",
"created_at": 1724005063,
"kind": 1,
"tags": [
[
"proxy",
"https://qoto.org/users/cyrilpedia/statuses/112984395870654545",
"activitypub"
]
],
"content": "For first-in-class oncology drugs 2010-2020 (n=50)\n\n'Remarkably, the number of drugs that originate from academic research alone was on par with that originated by large pharma (each 14% of our sample).'\n\nhttps://www.sciencedirect.com/science/article/pii/S1359644622004494?via%3Dihub",
"sig": "5c3e910b1229c557a4859c3498a30f24a3487cb4b69f9be03260dbfca05c83f2712ffc2bfc34f4a4c8d202942381c0b38ebb69b2b2b5e21a65064e06bcc84390"
}